Elafibranor 80mg

DRUG2 trials

Sponsors

Genfit, Ipsen

Conditions

Non Alcoholic SteatohepatitisPrimary Biliary Cirrhosis

Phase 2

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

TerminatedNCT03883607

GenfitNon Alcoholic Steatohepatitis

Start: 2019-06-25End: 2020-06-16Updated: 2021-10-28

Phase 3

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

Active, not recruitingNCT04526665

IpsenPrimary Biliary Cirrhosis

Start: 2020-09-24End: 2028-12-01Updated: 2026-09-01

Related Papers

Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis

Journal of Comparative Effectiveness Research2026-04-17

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in <scp>ELATIVE</scp>

Liver International2026-04-06

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

New England Journal of Medicine2023-11-13206 citations